Analysts expect NewLink Genetics Corp (NASDAQ:NLNK) to report earnings per share (EPS) of ($0.69) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for NewLink Genetics’ earnings. The lowest EPS estimate is ($0.80) and the highest is ($0.60). NewLink Genetics posted earnings of ($0.46) per share in the same quarter last year, which indicates a negative year over year growth rate of 50%. The firm is scheduled to announce its next quarterly earnings results on Tuesday, February 27th.
According to Zacks, analysts expect that NewLink Genetics will report full year earnings of ($2.65) per share for the current fiscal year, with EPS estimates ranging from ($2.80) to ($2.55). For the next year, analysts expect that the business will post earnings of ($2.40) per share, with EPS estimates ranging from ($3.02) to ($1.62). Zacks’ EPS averages are an average based on a survey of sell-side analysts that that provide coverage for NewLink Genetics.
A number of brokerages recently commented on NLNK. Cantor Fitzgerald set a $26.00 target price on NewLink Genetics and gave the stock a “buy” rating in a report on Monday, January 8th. BidaskClub raised NewLink Genetics from a “sell” rating to a “hold” rating in a report on Friday, January 5th. Zacks Investment Research cut NewLink Genetics from a “buy” rating to a “hold” rating in a report on Thursday, January 4th. Jefferies Group decreased their target price on NewLink Genetics from $26.00 to $25.00 and set a “buy” rating on the stock in a report on Friday, November 3rd. Finally, Stifel Nicolaus raised their target price on NewLink Genetics from $25.00 to $29.00 and gave the stock a “buy” rating in a report on Friday, November 3rd. One analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $23.29.
A number of large investors have recently bought and sold shares of NLNK. Wells Fargo & Company MN raised its holdings in NewLink Genetics by 1.8% during the second quarter. Wells Fargo & Company MN now owns 165,791 shares of the biotechnology company’s stock valued at $1,219,000 after acquiring an additional 2,865 shares during the period. Alliancebernstein L.P. raised its holdings in NewLink Genetics by 88.6% during the second quarter. Alliancebernstein L.P. now owns 61,300 shares of the biotechnology company’s stock valued at $451,000 after acquiring an additional 28,800 shares during the period. Northern Trust Corp raised its holdings in NewLink Genetics by 4.0% during the second quarter. Northern Trust Corp now owns 298,738 shares of the biotechnology company’s stock valued at $2,195,000 after acquiring an additional 11,532 shares during the period. Parametric Portfolio Associates LLC raised its holdings in NewLink Genetics by 21.5% during the second quarter. Parametric Portfolio Associates LLC now owns 27,972 shares of the biotechnology company’s stock valued at $206,000 after acquiring an additional 4,955 shares during the period. Finally, Dimensional Fund Advisors LP raised its holdings in NewLink Genetics by 40.2% during the second quarter. Dimensional Fund Advisors LP now owns 120,767 shares of the biotechnology company’s stock valued at $888,000 after acquiring an additional 34,624 shares during the period. 54.58% of the stock is currently owned by institutional investors and hedge funds.
TRADEMARK VIOLATION WARNING: “Analysts Expect NewLink Genetics Corp (NLNK) Will Post Earnings of -$0.69 Per Share” was reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://sportsperspectives.com/2018/02/24/analysts-expect-newlink-genetics-corp-nlnk-will-post-earnings-of-0-69-per-share.html.
NewLink Genetics Company Profile
NewLink Genetics Corporation is a clinical-stage immuno-oncology company focused on discovering, developing and commercializing immunotherapeutic products for the treatment of cancer. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NewLink Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewLink Genetics and related companies with MarketBeat.com's FREE daily email newsletter.